SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy (SWEAT CRYPTO) is trending as the community actively discusses its long-term potential and the opportunity to accumulate the move-to-earn token at a low valuation, despite its historical underperformance.

Synthetix is a decentralized perpetual futures protocol built on Ethereum Mainnet. Synthetix uses a hybrid design — off-chain order matching on a high-performance CLOB with on-chain settlement — to deliver low latency, deep liquidity, and MEV-resistant execution while keeping custody and finality on Ethereum. Traders get CEX-like performance with on-chain security and composability. The protocol’s liquidity is provided by the Synthetix Liquidity Provider (SLP) vault and backstopped by staked SNX collateral, which underwrites the issuance of the sUSD stablecoin and the solvency of the SLP vault.

Synthetix Network 

Synthetix (SNX) is seeing increased attention driven by its strategic return to Ethereum Mainnet for a new perps DEX, featuring an upcoming $1 million trading competition. The community is keenly discussing its potential, especially with the news of no more SNX token inflation and forthcoming buybacks, signaling enhanced utility and value.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is trending as its innovative NEAR Intents continue to drive cross-chain interoperability, notably with a recent Starknet integration, alongside its deepening commitment to AI through a NVIDIA Inception Program partnership and reported surge in active users, highlighting its growing influence as a Layer-1 blockchain.

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Lexeo Therapeutics Inc.

Lexeo Therapeutics is trending as positive interim clinical data for its LX2006 gene therapy in Friedreich's ataxia cardiomyopathy sparks community discussion and analyst upgrades, despite some investor questions surrounding recent price action and the path to accelerated approval.

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Transmedics Group Inc

TransMedics is trending due to the FDA's IDE approval for its next-generation OCS Heart trial and robust organ transport volumes, with many anticipating a short squeeze. Bullish sentiment is further fueled by the company's European expansion and the CEO's recent significant open-market stock purchase, signaling strong confidence in its growth trajectory.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following the FDA approval of BYSANTI for bipolar I disorder and schizophrenia, with its robust patent protection until 2044 igniting strong community speculation about the stock's undervaluation and its potential as a prime acquisition target for larger pharmaceutical companies. The community is also highly focused on its promising pipeline, including applications for Major Depressive Disorder and Tradipitant for GLP-1 induced nausea.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The semiconductor sector, as represented by SMH, continues to rally to new highs, driven by aggressive AI infrastructure spending projections from companies like OpenAI and robust forecasts from leading chipmakers. However, a significant debate rages in the community, with some seeing unstoppable growth fueled by relentless AI demand, while others warn of an unsustainable "AI bubble" due to intense capital expenditure and concerns over declining GPU rental rates.

Trimble, Inc. engages in providing advanced positioning, modeling, and data analytics technologies to connect the digital and physical worlds, enhancing productivity, safety, sustainability, and transparency. It operates through the following segments: AECO, Field Systems, and Transportation & Logistics. The AECO segment serves architects, engineers, contractors, and owners through various software and subscription offerings. The Field Systems segment offers hardware and software solutions for customers working in survey & mapping and civil construction. The Transportation & Logistics segment provides software and subscription offerings to shippers and carriers in North America and Europe. The company was founded by Charles Robert Trimble in 1978 and is headquartered in Westminster, CO.

Trimble Inc

Trimble is trending as robust industrial production data and a manufacturing rebound position its advanced technology solutions favorably within the sector. Community sentiment points to Trimble as a key player in the expanding robotics and automation markets, supported by analyst upgrades and the company's strategic focus on its 'Connect & Scale' initiatives.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's Entertainment (PLAY) is seeing active debate following a Q2 earnings report that missed profit and revenue expectations, yet the stock rallied on management's commentary about improving sequential sales trends and positive momentum. Investors are divided between concerns over the company's financial health and consumer discretionary spending, and optimism for a potential short squeeze fueled by high short interest and ongoing turnaround initiatives.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is trending following a recent earnings report that delivered a surprise profit and revenue growth, fueling a sharp debate among investors. While many view this as a turnaround signal, especially given high short interest, others express skepticism about its valuation and business model, citing concerns over market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Buy" by Brokerages

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) have earned a consensus recommendation of "Buy" from the seven analysts that are covering the company, MarketBeat Ratings...

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.8% - What's Next?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.8% - Time to Sell...

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.8% - Here's Why

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 3.8% - What's Next...

Cantor Fitzgerald Raises Eupraxia Pharmaceuticals (NASDAQ:EPRX) Price Target to $19.00

Cantor Fitzgerald upped their price target on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an "overweight" rating in a research report on Thursday...

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Rating of "Buy" from Analysts

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven analysts that are covering the stock, Marketbeat.com reports. One...

Short Interest in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Grows By 138.8%

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totaling 1,311,773...

Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus

Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health and maintained remission in EoE patients, with no serious safety issues reported.read more...

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 30.1% in December

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) saw a large increase in short interest in December. As of December 15th, there was short interest totaling 549,299 shares, an increase of...

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of "Buy" by Brokerages

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) have been assigned an average recommendation of "Buy" from the seven ratings firms that are covering the firm, MarketBeat...

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell, John Salvatore Montalbano and Amanda Malone on May 12, 2011 and is headquartered in Victoria, Canada.

EPRX
Eupraxia Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest EPRX News

EPRXEupraxia Pharmaceuticals Inc